消息出来了,Vascepa疗效显著。今晚股价如何表现不好预测,因为也可能买于预期,卖于事实。
CHICAGO, Nov. 10, 2018 (
GLOB E NEW
SWIR E) -- Amarin Corporation plc (
AMRN ) announced today the primary results from the Vascepa® (icosapent ethyl) cardiovascular (CV) outcomes trial, R
EDUC E-IT™, following presentation of the late-breaking clinical trial results at the 2018 Scientific Sessions of the American Heart Association (AHA) in Chicago, Illinois. REDUCE-IT primary results confirmed 25% relative risk reduction (RRR) for the topline primary endpoint result with multiple robust demonstrations of efficacy, including 20% reduction in cardiovascular death.
The active pharmaceutical ingredient in Vascepa has a unique molecular structure. Vascepa has demonstrated clinical effects that have not been shown for any other product.
[引用原文已无法访问]